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THE parasitic nature of tumour cells has attracted considerable attention and
several reports have appeared on the tumour-host relationship (Gurnani, Kumta
and Sahasrabudhe, 1956; Greenles and LePage, 1955; Mider, 1951 ; Greenstein,
1954; Greenberg and Sassenrath, 1955). In this context the rapid turnover of
nucleic acids (Tyner, Heidelberger and LePage, 1953; Barnum and Huseby,
1950; Griffin, Davies and Tifft, 1952; Hulbert and Potter, 1952) and the low
levels of pyridine nucleotides (PN) (Carruthers and Suntzeff, 1954; Strength,
Ringler and Nelson, 1954; Jedekin and Weinhouse, 1955; Glock and McLean,
1957) in tumour tissues calls for special attention. It appears that since adenine
is a constituent of nucleic acids and also of pyridine nucleotides, any drain on
this precursor from the metabolic pool in the nucleic acid synthesis of tumour
may deprive the host tissues of its availability for pyridine nucleotide synthesis.
Our own findings on levels of activity of the choline-dehydrogenase in the livers
of tumour-bearing animals were considerably lower than those observed in the
tissues of normal animals. It was further shown that this inherently diminished
enzyme activity could be reversed by fortification of the medium with DPN.
In the present communication two problems have been investigated: (i) the
influence ofthe tumour on the host tissues with respect to the pyridine nucleotide
levels and (ii) the availability or non-availability of adenine nucleotides in the
synthesis of pyridine nucleotides in host tissues. For this purpose, two types of
transplantable tumours: (a) fast growing ascites Yoshida sarcoma and (b)
comparatively slow growing fibrosarcoma have been used in Wistar rats and Swiss
mice respectively.
MATERIAL AND METHODS
Transplantable fibrosarcoma was maintained by subcutaneous injections of
tumour homogenates in 6-8-week-old Swiss mice. The tumour attains an
appreciable size in about 21 days. Yoshida sarcoma (ascites) obtained through
the courtesy of Professor H. Druckrey, of Freiburg, Germany, was maintained
by intraperitoneal transfer in Wistar rats. This tumour grows rapidly and
results in the death of animals in 7-8 days.
The levels of pyridine nucleotides in the livers and spleens of normal and
tumour-bearing animals have been estimated according to the method ofHuffand
Perlzweig (1947) as modified by Dianzani (1955). In another experiment with
Yoshida sarcoma the pyridine nucleotide levels of host tissues have been investi-
gated at different intervals of time after transplantation. The optimum time
and dose of nicotinamide required was determined in auxiliary experiments byPYRIDINE NOCLEOTIDE SYNTHESIS
injecting intraperitoneally 250, 500, and 1000 mg. of nicotinamideper kg. of body
weight and estimating the pyridine nucleotide synthesis in the livers and spleens
3, 6, 12 and 18 hours afterwards. In case of Swiss mice, nicotinamide was
administered at the dose of 500 mg. per kg. ofbody weightassuggestedbyKaplan
et al. (1956).
RESULTS AND DISCUSSION
The levels of pyridine nucleotides in the livers and spleens of control and
tumour-bearing animals are presented in Table I. It will be seen from this that
TABLE I.-Pyridine Nucleotide Levels in the Tissues from Normal and
Tumour-bearing Animals
Pyridine
nucleotide in
Number pg./g. wet tissue
Expt. and sex Age r-
A
·
No. Animals used of animals (months) Liver Spleen
1 . Swiss mice
(a) Control . ..4males 671±11 456±18 4 males~ 3-3i 561±i29 337±14 (b) Fibrosarcoma*-bearing . . . 5 ,, (16-4) (26 1) L(16.4) (26.1)
2 . Wistar rats
(a)Control females r 745±43 412±5
(b) Yoshida (ascites)t sarcoma-bearing 4 3 3-3} 550±34 327±19. (26.2) (20.6)
3 . Wistar rats
(a) Control . .7 males 1258±51 574±38
(b) Yoshida (ascites): sarcoma-bearing 53 5 716±36 470±23 [(43.-1) (18.0)
* Animals were sacrificed after 21 days. t Animals were sacrificed after 4 days. t Animals were
sacrificed after 6 days.
Figures in parenthesis indicate the percentage fall in the PN levels in tissues of tumour-bearing
animals as compared with the corresponding control animals.
the presence of the tumour brings about a lowering of pyridine nucleotide levels
in the host tissues. In case of slow growing fibrosarcoma in Swiss mice the
lowering in the levels of pyridine nucleotides is to the extent of 16.4 and 26-1
per cent in the livers and spleens respectively. In the fast growing Yoshida
sarcoma, however, the effects are more pronounced, the lowering in livers and
spleens being to the extent of 43-1 and 18-0 per cent respectively. It will be seen
from Table II that the decrease of pyridine nucleotide levels starts from 2nd day
TABLE II.-Pyridine Nucleotide Levels in the Host Tissues at Different
Intervals of Timefollowing Transplantation of Yoshida Sarcoma
Pyridine nucleotide levels
in ug./g. wet tissue
Days of
transplantation Liver Spleen
1 . 1120 590
2 . 904 544
3 . 976 412
4 . 721 508
6 . 675 502
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onwards. Pyridine nucleotide synthesized in the spleens and livers of fibro-
sarcoma-bearing Swiss mice, under the influence of intraperitoneal injection of
500 mg. ofnicotinamide per kg. body weight is givenin Table III. Itwill be seen
from this that the capacity for synthesis of pyridine nucleotides is considerably
diminished in the host tissues of tumour-bearing animals.
TABLE III.-Influence ofFibrosarcoma on Nicotinamide Stimulated in vivo
Synthesis ofPyridine Nucleotide in Host Tissues ofSwiss Mice
Amount of pyridine nucleotides
in Ag./g. of wet tissue in
Liver Spleen
Tumour- Tumour- Tumour
Control bearing Control bearing fibro-
animalsanimalani nimals animals sarcoma
Initial levels . . . . . 671 561 456 337 119
Levels after administration ofnicotinamide* . 3063 1334 2900 872 611
Net synthesis in 12 hours . .. 2392 773 2444 535 492
* Animals were injected 500 mg. of nicotinamide, per kg. body weight and sacrificed after 12
hours.
The influence exerted by Yoshida sarcoma on the synthesis of pyridine
nucleotides in the host spleen is given in Fig. 1. It will be seen that there is a
0.
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.
CA.
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FIG. 1.-Net synthesis of pyridine nucleotides by spleens of normal and tumour-bearing (Yoshida sarcoma) rats. Nicotinamide was injected at 500 mg. and 1000 mg. per kg. body
weight on the 4th day after tumour transplantation. Initial levels of pyridine nucleotides
(PN) were 412 and 327 pg. per g. in the spleens of normal and tumour-bearing animals
respectively.
. oNormal spleens. 0 0 Spleen from tumour-bearing
*· *jNormal spleens. 0 0f animalls.
decreased utilization of nicotinamide for pyridine nucleotide synthesis in the host
tissues. During the 3 hour period, the normal spleens synthesize 548 pg. of
pyridine nucleotide per g. of tissue, whereas the spleens from the tumour-bearing
animals show a negligible response. The differences in the utilization of nico-
tinamide in these two groups become more marked after 12 hours which is the
optimum period for pyridine nucleotide synthesis (Table IV). Thus, while thePYRIDINE NUCLEOTIDE SYNTHESIS
TABLE IV.-Influence ofNicotinamide Administration on Pyridine
Nucleotide Levels ofLiver and Spleen ofNormal Rats
Dose of
Time after of nicotinamide in
nicotinamde injection mg./ k. bodyweight
Control-
(No nicotinamide injected) .
3 hours after
6 hours after
12 hours after .
18 hours after .
250
500
1000
250
500
1000
250
500
1000
250
500
1000
PN levels in ,g./g. of
Liver Spleen
745 412
1320
1550
1595
2080
2180
2550
1765
1295
2052
1150
1400
1175
648
960
765
1060
940
900
1045
1482
1285
550
640
710
pyridine nucleotide synthesis in controls is 1070 /ug. per g., the tumour-bearing
animals show a net synthesis of only 133 zg. per g. of tissue. Similar influence
of the tumour on the pyridine nucleotide synthesis of host livers is evident from
Hours afternicotinamideadministration
FIa. 2.-Net synthesis of PN by livers of normal and tumour-bearing (Yoshida sarcoma)
rats. Nicotinamide was injected at 500 mg. and 1000 mg. per kg. body weight on the 4th
day after tumour transplanrtation. Initial levels of pyridine nucleotides (PN) were 745
and 550 pg. per g. in the livers of normal and tumour-bearing animals respectively.
:-.....}Normal livers. O- - -- -O }Livers fromtumour-bearing · · O~~~~~~~~~O animals.
Fig. 2. With 500 mg. dose, the livers from the tumour-bearing animals synthesize
570 ,ug. of pyridine nucleotides per g., while in normal animals the net synthesis
is 1605/g. per g. of tissue.
These results clearly demonstrate that the presence of fibrosarcoma and
Yoshida sarcoma in the body impairs the utilization of nicotinamide for pyridine
nucleotide synthesis in host tissues. Whether this is due to a release of an
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inhibitory substance by the tumour as has recently been suggested by Waravdekar
and Powers (1957), or whether it originates from a competition between the nucleic
acids and the pyridine nucleotides for adenine moiety of the metabolic pool is
yet undecided and further work is in progress to elucidate this.
SUMMARY
1. Pyridine nucleotide levels and utilization of nicotinamide for in vivo
pyridine nucleotide synthesis have been investigated in the host livers and spleens
of tumour-bearing animals.
2. It was shown that thepyridine nucleotide levels andthe net in vivo synthesis
ofpyridine nucleotides are decreased in the host tissues.
3. A preferential utilization of adenine moiety for nucleic acid synthesis by
tumour tissue and its consequent non-availability for pyridine nucleotide syn-
thesis in host tissues has been suggested.
Grateful thanks are due to Dr. V. R. Khanolkar and Dr. A. R. Gopal-Ayengar
for helpful suggestions and criticism.
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